Laser technology has long been a standard treatment for many diseases. In particular, laser treatment is considered the standard of care in various urological diseases. While originally primarily restricted to stone treatment, lasers have since evolved to play an important role even in the treatment of malignant diseases. In this review, we take a closer look at the history of lasers in urology and some implications for treatments today.
Upper tract urothelial carcinoma (UTUC) is a relatively rare disease with an aggressive phenotype compared to urothelial carcinoma in the bladder. In recent years, kidney-sparing surgery (KSS) and, in particular, endoscopic surgery have become the procedure of choice among urologists where the treatment of localized UTUC is concerned. Endoscopy tends to result in satisfactory oncological disease control while lowering morbidity and minimizing complications amongst the appropriately selected cohort of patients. While endoscopic surgery for UTUC might appear to be standardized, it, in fact, differs considerably depending on the source of energy used for resection/ablation. There has been little reliable data up to now on which laser energy source is the most superior. The goal of this review is, therefore, to outline the results of endoscopic UTUC treatment using different lasers and to analyze how these laser-tissue interactions may affect the surgery. We start by pointing out that the data remains insufficient when trying to determine which laser is the most effective in the endoscopic management of UTUC. The ever-growing number of indications for minimally invasive treatment and the increasing number of centers using laser surgery will, hopefully, lead to novel randomized controlled trials that compare the performance characteristics of the lasers as well as the effects of UTUC on patients.
Purpose The aim of this research was to compare the csPCa detection rate (ISUP≥2) for the 4 biopsy methods: TRUS-GB, COG-TB, FUS-TB and TPMB. Materials and methods The inclusion criteria were as follows: PSA>2 ng/mL, and/or positive DRE, and/or suspicious lesion on TRUS and Pi-RADSv2.1≥3 score. In total, 102 patients were enrolled in the study. Biopsies were performed by two urologists. In a single procedure, the first urologist performed a FUS-TB and TPMB followed by second urologist who performed TRUS-GB and COG-GB. All specimens were obtained within a single procedure. Results The CsPCa detection rate and overall CDR per patient were comparable among the respective biopsy methods (p>0.05). Compared with other biopsy methods, a lower cisPCa was detected using COG-TB (p=0.004). The positive cores percentage ratio (p<0.001) as well as positive cores containing csPCa percentage ratio (p<0.001) significantly increased for the targeted biopsy methods. The median MCCL (p=0.52) as well the median for the MCCL of csPCa (p=0.47) did not differ significantly among the respective biopsy methods. Concordance of the Gleason scores between biopsy and post-prostatectomy pathology didn’t differ significantly among biopsy methods (p=0.87). For TRUS-GB, FUS-TB and TPMB, the common predictive factors for csPCa were positive DRE, suspicious lesion on US and Pi-RADS 5. As for COG-TB, the only predictor was Pi-RADS 5. Conclusion The targeted methods did not show an increase in csPCa and overall CDR over systematic ones in patients with Pi-RADS≥3. A lower cisPCa was detected using COG-TB in comparison with the other methods. The sampling efficiency increased for the targeted biopsy methods which used only a proportion of positive cores and cores containing csPCa. There was no statistical difference in histology concordance among the biopsies. One common predictive factor of increased csPCa detection for all biopsy methods was Pi-RADS 5.